Menu Search
Equities

Teva Pharmaceutical Industries Ltd

TEVAN:MEX

Teva Pharmaceutical Industries Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (MXN)350.20
  • Today's Change2.99 / 0.86%
  • Shares traded168.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 12 2024 20:27 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Teva Pharmaceutical Industries Ltd grew revenues 6.17% from 14.93bn to 15.85bn. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -2.45bn to -559.00m.
Gross margin51.01%
Net profit margin-7.46%
Operating margin2.67%
Return on assets-2.99%
Return on equity-15.28%
Return on investment-4.34%
More ▼

Cash flow in USDView more

In 2023, Teva Pharmaceutical Industries Ltd increased its cash reserves by 13.87%, or 393.00m. The company earned 1.37bn from its operations for a Cash Flow Margin of 8.63%. In addition the company generated 968.00m cash from investing, though they paid out 1.91bn more in financing than they received.
Cash flow per share-0.1739
Price/Cash flow per share--
Book value per share5.35
Tangible book value per share-13.08
More ▼

Balance sheet in USDView more

Teva Pharmaceutical Industries Ltd has a Debt to Total Capital ratio of 74.83%, a lower figure than the previous year's 266.88%.
Current ratio0.8925
Quick ratio0.6056
Total debt/total equity3.13
Total debt/total capital0.7483
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.